Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vanucizumab vs Bevacizumab with mFOLFOX-6 in mCRC
NCT02141295Phase 2Terminated
- Sponsor
- Roche
- Start
- Jun 2014
- Primary completion
- Jul 2016
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of faricimab in metastatic colorectal cancer (mCRC), sponsored by Roche. Started Jun 2014; status: terminated.
02
Drugs
faricimab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02141295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02141295.